Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by PitchinPennieson Mar 07, 2021 1:59pm
108 Views
Post# 32739209

RE:Two Years ago Mr. Meir tried to save

RE:Two Years ago Mr. Meir tried to save Knight Therapeutics is to this day a one-man band, made up of Jonathan and his handful of acolytes. If there is any doubt about this, please refer to the trading symbol and the "hilarious" opening slide he still uses for his pitch deck, which offers knee-slapping wordplay on his surname. It was a cute monologue when it looked as if he alone might know what he's doing in establishing this oddball second-act.

The clash with Meir was a gut-check. Now investors simply get to watch Jonathan playing 3D chess with himself and his invisible adversaries, while the share price sinks.

Yes, it takes time and infinite patience to do what he once did at Paladin, and, yes, it's a worthwhile vision. But there's an alternative interpretation, which is that the world has changed since JG's hey-day and the pharma business has changed drastically, too. What hasn't changed one whit is Jonathan. He's got the same suits, same line of patter, same daddy issues, same giggling at things no one else sees or understands. I like the guy, and if you told me three years ago that I wouldn't be backing up the truck to acquire shares if they ever went below five bucks, I just wouldn't have believed it.

Something does smell a little off lately. I'll keep an eye on GUD, but I'm not a buyer this week or next. 
<< Previous
Bullboard Posts
Next >>